Pfizer (PFE) Shares Bought by Family Legacy Inc.

Family Legacy Inc. increased its stake in shares of Pfizer (NYSE:PFE) by 72.5% in the fourth quarter, Holdings Channel reports. The institutional investor owned 24,148 shares of the biopharmaceutical company’s stock after buying an additional 10,148 shares during the quarter. Family Legacy Inc.’s holdings in Pfizer were worth $875,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Peregrine Asset Advisers Inc. increased its stake in shares of Pfizer by 0.5% in the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC boosted its position in shares of Pfizer by 0.8% in the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 50 shares during the period. Stone House Investment Management LLC boosted its position in shares of Pfizer by 1.0% in the second quarter. Stone House Investment Management LLC now owns 7,236 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 72 shares during the period. Highland Private Wealth Management boosted its position in shares of Pfizer by 0.8% in the second quarter. Highland Private Wealth Management now owns 9,047 shares of the biopharmaceutical company’s stock valued at $304,000 after acquiring an additional 76 shares during the period. Finally, Autus Asset Management LLC boosted its position in shares of Pfizer by 1.2% in the second quarter. Autus Asset Management LLC now owns 6,681 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 78 shares during the period. Institutional investors and hedge funds own 71.21% of the company’s stock.

A number of equities analysts have recently commented on PFE shares. SunTrust Banks restated a “hold” rating and issued a $40.00 price objective (up from $33.00) on shares of Pfizer in a research report on Monday, January 29th. Jefferies Group set a $39.00 price objective on shares of Pfizer and gave the company a “hold” rating in a research report on Monday, February 26th. Morningstar set a $38.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Tuesday, January 30th. BMO Capital Markets set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, March 6th. Finally, Vetr lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $37.98 price objective for the company. in a research report on Monday, January 15th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and an average price target of $39.20.



Shares of Pfizer stock opened at $36.32 on Friday. Pfizer has a 1 year low of $31.67 and a 1 year high of $39.43. The company has a market cap of $213,053.03, a price-to-earnings ratio of 13.71, a P/E/G ratio of 1.79 and a beta of 0.90. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The business had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. During the same period in the previous year, the business posted $0.47 earnings per share. Pfizer’s revenue for the quarter was up .6% on a year-over-year basis. equities research analysts predict that Pfizer will post 2.96 earnings per share for the current fiscal year.

Pfizer announced that its Board of Directors has authorized a share buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its stock is undervalued.

In other news, insider Mikael Dolsten sold 69,699 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $36.59, for a total value of $2,550,286.41. Following the completion of the sale, the insider now directly owns 120,784 shares in the company, valued at approximately $4,419,486.56. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director W Don Cornwell sold 1,758 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the sale, the director now owns 1,000 shares of the company’s stock, valued at $36,790. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 248,037 shares of company stock valued at $9,064,785. Company insiders own 0.06% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://dakotafinancialnews.com/2018/04/14/pfizer-pfe-shares-bought-by-family-legacy-inc.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply